Researchers from the Francis Crick Institute have found that some particularly aggressive lung cancer cells can develop their own electric network, like that seen in the body's nervous system.

AdvanCell is developing therapies to treat cancers including: prostate, skin, pancreatic, breast, bladder, colorectal, kidney ...

Barclays analyst Peter Lawson raised the firm’s price target on Exelixis (EXEL) to $29 from $25 and keeps an Equal Weight rating on the shares ...

Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. See why I ...

Morgan Stanley (NYSE:MS) analysts adjusted their stance on Ipsen SA (EPA:IPN:FP) (OTC: IPSEF), downgrading the stock from Equalweight to Underweight. The firm also set a new price target of EUR120.00 ...

Citi raised the firm’s price target on Exelixis (EXEL) to $45 from $38 and keeps a Buy rating on the shares following the Q4 report. The ...

Pancreatic enzyme replacement therapy (Pert) provides the enzymes people affected by pancreatic cancer need to absorb ...

CEO Mike Morrissey highlighted significant momentum in 2024, emphasizing the company's goal of achieving $3 billion in annual cabozantinib (Cabo) revenue by 2030 and $5 billion for zanzalintinib ...

How common is endometrial cancer? In the United States, cancer of the endometrium (the lining of the uterus) is the most common cancer of the female reproductive organs. The American Cancer Society ...

Lantheus, a Massachusetts-based developer of radiopharmaceuticals, has agreed to acquire the radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics. Lantheus ...